호스피스 수가 제도화를 눈 앞에 두고

박진노,Park, Jin-No 한국가톨릭호스피스협회 2008 호스피스 Vol.41 No.-

초대석 - 가정호스피스 활성화의 걸림돌과 미래 가정호스피스의 필요성

박진노,Park, Jin-No 한국가톨릭호스피스협회 2009 호스피스 Vol.45 No.-

포스타 전시 발표 : 혈액종양 ; Mitomycin-C를 포함한 술후 화학요법후 발생한 혈전성 혈소판 감소성 자반증/용혈성 요독증후군

박진노,송치원,김기원,한지연,조석구,강진형,박석영,홍영선,김훈교,이경식 대한내과학회 1999 대한내과학회 추계학술대회 Vol.57 No.-

암 환자 병명통고

박진노,최소은,최경미,홍영선,이경식,양수,Park, Jean-No,Choi, So-Eun,Choi, Kyung-Mee,Hong, Young-Seon,Lee, Kyung-Shik,Yang, Soo 한국호스피스완화의료학회 2004 한국호스피스.완화의료학회지 Vol.7 No.2

목적: 환자, 가족, 의료진(의사, 간호사), 의과대학생, 간호대학생들의 시간의 흐름에 따른 병명통고에 대한 태도 변화를 알아보는 것이다. 방법: 2002년 10월부터 3 개월 간 가톨릭대학교 의과대학 부속 성모병원에서 전이성 암 환자, 조사대상 암 환자의 주 보호자, 암 환자의 간호 및 치료에 관련된 의료진(의사 및 간호사), 임상 실습 중인 의과 대학생, 간호대학생을 대상으로 각 군 50명씩 등록하여 암 환자의 병명통고에 관한 설문 조사를 실시하였다. 설문자료 평가 항목은 병명통고에 대한 찬성여부, 시기여부, 통고방법, 통고를 받기를 원하는 이유, 적합한 병명통고자가 누구인지였다. 환자 50명, 주 보호자 50명, 의료진 51명, 의과대학생 41명과 간호대학생 50명을 대상으로 하였다. 전이성 암환자 50명을 대상으로 하기로 하였으나, 전이성 암환자 34명만이 등록되었으며, 이외에 림프종 환자 16명을 포함하여 총 50명의 환자에게 설문조사를 진행하였다. 결과: 모든 설문 응답자들 가운데 89.3%가 병명통고에 찬성하였다(환자 98.0%, 주 보호자 88.0%, 의료진 90.2%, 의과대학생 73.2%, 간호대학생 94.0%). 림프종 환자를 제외한 진행성 암환자 34명을 대상으로 97.1%가 동의하였다. 병명통고 시기는 79.8%에서 진단 즉시 해주는 것을 선호하였다(환자 94.0%, 주 보호자 80.0%, 의료진 68.6%, 의과대학생 68.3%, 간호대학생 86.0%). 병명통고 방법은 64.4%에서 모든 내용을 한 번에 정확히 설명해주는 것을 선호하였다(환자 81.6%, 주 보호자 66.0%, 의료진 56%, 의과대학생 48.8%, 간호대학생 70.0%). 병명통고에 동의하는 이유에 대해서 모든 군에서 치료 참여가 가능한 것을 가장 큰 이유로 들었다. 병명통고를 누가하느냐는 문제에 대해서는 86.4%에서 의사가 병명통고를 하는 것이 적합하다고 응답하였다. 결론: 환자, 주 보호자, 의료진, 의과대학생 및 간호대학생의 병명통고에 대한 찬성률은 증가하였다. 병명통고 찬성 이유로 치료에 참여가 가능하다는 것을 가장 많이 선택하였다. 통고시기와 방법은 진단 즉시 모든 내용을 한 번에 정확히 알려주기를 원하였다. Purpose: The aim of the study was to assess changes of the attitudes and opinions about disclosure of cancer diagnosis to patients. Methods: We analyzed the attitudes and opinions of in-patients with metastatic cancer, their families, physicians, nurses, medical students, nursing students. Three questionnaires were used for in-patients, families, and surroundings in hospital. Data was collected in the St. Mary hospital for 3 months from October, 2002. We investigated the preference of disclosure, the reason the patients should be informed of disclosure, when, how and who to tell the cancer diagnosis to patients. 242 persons participated in these questionnaires (50 in-patients, 50 their families, 51 physicians and nurses, 41 medical students, 50 nursing students). Only 34 in-patients with metastatic cancer were enrolled, and so 16 in-patients with lymphoma were added. All in-patients were undergoing anticancer chemotherapy. Results: 89.3% of the participants wanted to be told about disclosure of cancer and terminal illness (in-patients 98.0%, their families 88.0%, physicians and nurses 90.2%, medical students 73.2%, nursing students 94.0%, in-patients with metastatic cancer 97.1%). 79.8% of the respondents hoped that the moment to tell the truth was immediately when the disease was diagnosed (in-patients 94.0%, their families 80.0%, physicians and nurses 68.6%, medical students 68.3%, nursing students 86.0%). 64.4% of all prefered to be told the truth once for alt including patients' diagnosis, present status and prognosis (in-patients 81.6%, their families 66.0%, physicians and nurses 56.0%, medical students 48.8%, nursing students 70.0%). Most indicated the first reason to be told the truth was the possibility to participate in treatment design. 86.4% responded that physicians were the proper persons to disclose the diagnosis. Conclusion: Not only in-patients, families but also physicians, nurses, medical students and nursing students all preferred the disclosure of cancer diagnosis. This preference was increased compared with the previous papers. The first reason to be told the truth was the possibility to participate in treatment design. Most of the participants wanted to be told the truth once for all.

악성 림프종 환자에서 BEAM 고용량화학요법과 자가조혈모세포이식

박진노(Jin No Park),홍영선(Young Seon Hong),송치원(Chee Won Song),조석구(Seok Goo Cho),이종욱(Jong Wook Lee),민우성(Woo Sung Min),김춘추(Chun Choo Kim),이경식(Kyung Shick Lee) 대한내과학회 2001 대한내과학회지 Vol.61 No.3

N/A Background : The long-term survival in patients with non-Hodgkin's lymphoma (NHL) after conventional chemotherapy is about 35% and the rest of the patients tend to have relapse. So, in relapsed or refractory NHL, the outcome of patients undergoing high-dose chemotherapy and autologous peripheral stem cell transplantation (APBSCT) was evaluated, and the main prognostic factors were determined. Methods : 17 patients with relapsed or resistant NHL (5 complete response group, 7 partial response group, 4 primary refractory group, 1 resistant relapse) underwent BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy and APBSCT between July 1997 and February 1999. Results : The median follow-up duration was 17 months (range: 4-47). The response rate was 58.3% (complete response 33.3%, partial response 25.0%) in 12 patients in whom complete response group was not included. The 2-year, 3-year overall response rate were 41.2%, 27.5%, respectively. And 2-year progression free survival was 35.3%. The disease status before high-dose chemotherapy was the only significant prognostic factor in determining overall survival (univariate p=.024, multivariate p=.059) and progression free survival (univariate p=.013, multivariate p=.026). Patients with complete response to salvage regimen had better overall survival (p=.021) and progression free survival (p=.008) than patients with refractory response. WBC (≥ 1,000/uL) was recovered at the median 11 days (range; 8-24), and platelet (≥ 50,000/uL) was recovered at the median 18 days (range; 9-44). There was no treatment-related death and no grade 3 and 4 toxicity. Neutropenic infection was in 4 patients (1 Herpes zoster, 1 typhlitis, 1 perianal infection, 1 otitis externa). Conclusion : The pre-transplant disease status was the main prognostic factor. Patients with complete response to salvage regimen had the significant benefit in survival from high-dose chemotherapy and APBSCT, but patients with refractory or resistant relapsed NHL did not have any significant benefit.(Korean J Med 61:255-263, 2001)

표준형 성인 암성 통증평가 도구 개발을 위한 암성 통증 어휘조사

장세권,박진노,염창환,이명아,송찬희,윤소영,이영희,최윤선,Jang, Se-Kwon,Park, Jean-No,Yeom, Chang-Hwan,Lee, Myung-Aha,Song, Chan-Hee,Yoon, So-Young,Lee, Young-Hee,Choi, Youn-Seon 한국호스피스완화의료학회 2003 한국호스피스.완화의료학회지 Vol.6 No.1

배경 : 통증은 암환자가 겪는 가장 흔한 증상 중 하나로, 정확한 통증 평가는 적절한 통증 치료를 위해 필수적이다. 한편 통증은 주관적인 문제이기 때문에 환자의 표현은 통증 상태의 가장 믿을만한 지표이다. 이에 실제 암 환자의 통증 표현 어휘를 조사하구 통증의 성격에 따른 통증어휘를 분석함으로 효율적인 통증평가 및 조절에 도움이 되고자 하였다. 방법 : 2002년 9월부터 11월 사이 서울과 경기도에 위치한 6개 대학병원에서 암진단을 받고 치료 중인 75명의 환자를 대상으로 조사자가 직접 면담하여 환자가 표현하는 통증 어휘를 조사하였고, 통증의 성격에 따른 어휘를 분류하였다. 수집된 통증 어휘를 7차례의 자문회의와 실무회의를 거쳐 정리하였고, 표준형 성인 암성 통증평가 도구'를 위해 통증의 성격 범주당 각 5개의 통증 어휘를 선정하였다. 결과 : 183개(중복포함)의 통증 표현 어휘가 추출되었고, 52종류의 어휘로 표준화되었다. 체성 통증, 내장성 통증, 신경병증성 통증 모두에서 '쑤시다'가 가장 빈도가 높았고, '결리다', '끊어지는 듯하다', '지긋이 아프다', '채찍으로 후리는 듯하다'는 체성 통증에서만 나타나면서 빈도가 높은 표현이었고, '쓰리다', '뒤틀리다', '묵직하다', '짓누르다'는 내장성 통증에서, '따갑다', '저리다'는 신경병증성 통증에서만 나타나면서 빈도가 높았다. 결론 : 통증의 성격을 대표하는 어휘를 각각 5개씩 선택하였는데, 체성 통증의 경우 '쑤시다', '결리다', '찢어지는 듯하다', '뻐개지는 듯하다', '찌르다'가, 내장성 통증의 경우 '쑤시다', '뻐근하다', '쓰리다', '뒤틀리다', '쥐어짜는 듯하다'가, 신경병성 통증의 경우 '화끈거리다', '저리다', '뻗치다', '찌릿찌릿하다', '피부가 닿기만해도 아프다'가 선정되었다. This paper addresses the minor differences in the description of pain in Korean language in order to develop a standarized cancer pain aneument tool for Korean adults, Korean Caancer Pain Assessement Tool. The subtle differences in the meaning of expressions used cannot be translated into English and therefore we omiltted the English abstract.

표준형 성인 암성 통증 평가 도구(K-CPAT): 설문조사의 신뢰도 및 타당도 평가

최윤선,박진노,이명아,염창환,장세권,이준영,Choi, Youn-Seon,Park, Jin-No,Lee, Myung-Ah,Yeom, Chang-Hwan,Jang, Se-Kwon,Lee, June-Young 한국호스피스완화의료학회 2003 한국호스피스.완화의료학회지 Vol.6 No.2

Pupose : The Korean cancer pain assessment tool (K-CPAT) was developed in 2003 is consisted of questions concerning the pain location, quality of pain, present pain intensity, symptoms associated with pain, and psychosocial/spiritual pain assessments. This study was done to evaluate the reliability and validity of K-CPAT. Methods : A Stratified, proportional-quota, clustered, systematic sampling has been employed. Study population (903 cancer patients) was 1% of the target population (90,252 cancer patients). A total of 314 (34.8%) questionnaires have been collected. Results : Average pain score (5 Likert scale) by cancer type and at-present average pain score (VAS, $0{\sim}10$) were correlated (r=0.56, P<0.0001), and showed a moderate agreement (kappa=0.364). Mean score of satisfaction was 3.8 ($1{\sim}5$). The average time of completion of the questionnaire was 8.9 minutes. Conclusions: The K-CAPT is a reliable and valid instrument for the assessment of Cancer Pain for Korean.

경막외로 전이된 원발성 간암 1예

한혁준,박진노,노대근,방춘상,박수헌,최명규,정규원,선희식,강창석 大韓消化器病學會 1997 大韓消化器病學會誌 Vol.30 No.1

유방암 환자에서 고용량화학요법과 자가조혈모세포이식

송치원,박진노,민창기,조석구,김동욱,이종욱,홍영선,민우성,김춘추,이경식 대한내과학회 1999 대한내과학회 추계학술대회 Vol.57 No.-

위암세포에서 세포유착물질의 발현 및 위암세포의 복막 내피세포에 대한 결합 능에 미치는 retinoicacid의 영향

홍영선,박조현,박진노,이경식,김인철,Hong, Young Seon,Park, Cho Hyun,Park, Jin-No,Lee, Kyung Shik,Kim, In Chul 대한면역학회 2001 Immune Network Vol.1 No.1

Background : Peritoneal metastasis is one of the maj or types of the stomach cancer recurrence and the role of the adhesion molecules is thought to be very much important in this event. Retinoic acid (RA) has been known to induce the growth inhibition and differentiation of various malignancies, and apoptpsis and the change of expression of adhesion molecules have been reported to be involved in the action of RA. Methods : We studied the adhesion abilities of SNU-1, SNU-5, and SNU-6 cells to the peritoneal endothelial cells as well as the expression of the adhesion molecules (CD44, ICAM-1) in Western blot analysis. And also we studied the expression of apoptosis and the change of expression patterns of the various isoforms of CD44 and the change of the adhsion abilities of the cell line cells after RA treatment. Results: CD44 was expressed in SNU-5 and -16, together with an isoform in SNU-16. ICAM-1 was not expressed in any of the cell line cells tested. After the treatment of RA in the concentration range of $1-5{\times}10^{-5}M$ to three stomach cancer cell lines, growth inhibition, apoptosis and the change of expression of the CD44 were noted. After RA treatment, the expression of CD44H was weakly increased in SNU-1, and was markedly increased in SNU-5. In SNU-16, the expression of CD44H was decreased while that of CD44E were markedly increased. The adhesibility of cells to peritoneal cells was increased in relation with the increase of the CD44H expression, which shows the fact that the adhesibility of tumor cells to peritoneal mesothelial cells is mediated by CD44H recognizing hyaluronic acid. Conclusion : RA induces growth inhibition of stomach cancer cell line cells and increase the adhesiblity of stomach cancer cell line cells to peritoneal mesothelium. It is believed that RA decreases the metastatic ability of stomach cancer cells by upregulating the CD44H expression.